Meta-analysis of Major Cardiovascular outcome trials (CVOT) of glucagon-like peptide-1 receptor agonists (GLP-1 RA) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) demonstrated reduction of major adverse cardiovascular events (MACE), cardiovascular deaths (CVD), and renal outcomes.
Six trials of GLP-1 RA (51 762 subjects) and 4 trials of SGLT2i (33 457 subjects) showed both drug classes reduced MACE and CVD versus controls, with neither class preferred. This analysis shows that both classes of medications, GLP-1 RA and SGLT2i, demonstrate renal benefit.
The meta-analysis concluded that GLP-1 RA and SGLT2i showed a similar reduction in MACE, CVD, and renal outcomes. SGLT2i has advantages over GLP-1 RA in a reduction in HHF.